Lv21
130 积分 2024-10-28 加入
New biomarkers for antibody-drug conjugates in lung cancer the pathologist’s perspective
2小时前
待确认
Durable Gains and Persistent Questions From the ASTRUM-005 Trial
15天前
已完结
Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer
1个月前
已完结
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates
4个月前
已关闭
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
5个月前
已完结
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
6个月前
已完结
Cancer pain experiences in adult patients with cancer: A qualitative meta-ethnography
6个月前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
7个月前
已关闭
Rethinking Survival Metrics in EGFR-Mutated NSCLC: Insights from RMST Analysis of FLAURA2 and MARIPOSA
8个月前
已关闭
皖公网安备34019202002308
